MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


0026-895X/03/6403-629-639$20.00
Mol Pharmacol 64:629-639, 2003

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sarnago, S.
Right arrow Articles by Murga, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sarnago, S.
Right arrow Articles by Murga, C.

Involvement of Intramolecular Interactions in the Regulation of G Protein-Coupled Receptor Kinase 2

Susana Sarnago, Ramón Roca, Antonio De Blasi, Alfonso Valencia, Federico Mayor, Jr., and Cristina Murga

Centro de Biología Molecular "Severo Ochoa" (S.S., F.M., C.M.) and Centro Nacional de Biotecnología (R.R., A.V.), Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, Madrid, Spain; and INM Neuromed, Pozzilli, Italy (A.d.B.)

The G protein-coupled receptor (GPCR) kinase GRK2 phosphorylates G protein-coupled receptors in an agonist-dependent manner. GRK2 activity is modulated through interactions of diverse domains of the kinase with G protein {beta}{gamma} subunits, several lipids, anchoring proteins, and activated receptors. We report that kinase activity toward either GPCR (rhodopsin) or a synthetic peptide substrate is enhanced in the presence of GST-GRK2 fusion proteins or peptides corresponding to either N- or C-terminal sequences of GRK2. This direct stimulatory action of intrinsic domains on GRK2 activity does not add to the effect of other regulators, such as G{beta}{gamma} subunits, and strongly suggests the existence of some mode of autoregulation. The existence of regulatory intramolecular interactions in GRK2 is supported by the facts that a C-terminal peptide protects the N-terminal region from proteolytic cleavage and that two domains of GRK2 independently coexpressed in cells associate as assessed by immunoprecipitation. Molecular modeling suggests that intramolecular interactions among the N-terminal, C-terminal and kinase domains would keep GRK2 in a constrained conformation characteristic of an inactive, basal state. Our model proposes that disruption of such intramolecular contacts by intermolecular interactions with regulatory proteins (mimicked by exogenously added kinase fragments in vitro) would promote the conformational changes required to bring about GRK2 translocation and activation.


Received March 3, 2003; accepted May 20, 2003

Address correspondence to: Dr. Federico Mayor, Jr., Centro de Biología Molecular "Severo Ochoa", Consejo Superior de Investigaciones Científicas-Universidad Autónoma de Madrid, 28049 Madrid, Spain. E-mail: fmayor{at}cbm.uam.es




This article has been cited by other articles:


Home page
Cardiovasc ResHome page
P. Penela, C. Murga, C. Ribas, A. S. Tutor, S. Peregrin, and F. Mayor Jr.
Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease
Cardiovasc Res, January 1, 2006; 69(1): 46 - 56.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J.-H. Wu, R. Goswami, L. K. Kim, W. E. Miller, K. Peppel, and N. J. Freedman
The Platelet-derived Growth Factor Receptor-{beta} Phosphorylates and Activates G Protein-coupled Receptor Kinase-2: A MECHANISM FOR FEEDBACK INHIBITION
J. Biol. Chem., September 2, 2005; 280(35): 31027 - 31035.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2003 by the American Society for Pharmacology and Experimental Therapeutics